Literature DB >> 8094161

Fatal hepatic failure with liposomal doxorubicin.

U R Hengge, N H Brockmeyer, R Rasshofer, M Goos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8094161     DOI： 10.1016/0140-6736(93)90198-p

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.

Authors:  A J Coukell; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 2.  Liposomal formulations of cytotoxic drugs.

Authors:  R Janknegt
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

Review 3.  Safety aspects of pegylated liposomal doxorubicin in patients with cancer.

Authors:  D S Alberts; D J Garcia
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 4.  Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials.

Authors:  Melissa Anne Tutty; Dania Movia; Adriele Prina-Mello
Journal:  Drug Deliv Transl Res       Date:  2022-05-04       Impact factor: 5.671

5.  Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.

Authors:  F D Goebel; D Goldstein; M Goos; H Jablonowski; J S Stewart
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.